The Association for Accessible Medicines’ annual U.S. Generic & Biosimilar Medicines Savings Report, in partnership with the IQVIA Institute, reveals that the use of Food and Drug Administration ...

The U.S. health-care system is at a crossroads. Generic drugs and biosimilars have the potential to reduce costs and improve access to life-saving treatments, but outdated policies and entrenched ...

How long before the biosimilar market looks like the generics market? While still a relatively new area of biopharma, the biosimilar market has been getting more and more competitive, with huge ...

India's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, ...

India pharma sector moves beyond generics to biosimilars, biologics and AI-driven manufacturing, strengthening exports and ...

Biosimilars are near-identical versions of biologic cancer drugs, available at lower costs. Germany saves hundreds of millions annually from just one biosimilar drug. Patient mistrust and policy ...

Throughout the year, Teva had momentum in innovative medicines, scaling its global generics and biosimilars portfolio. On the brand side, Teva said it continued to showcase strong performance of its ...

AMRX reaffirmed 2026 revenue guidance of $3.05B-$3.15B and raised EBITDA and EPS outlook. Affordable Medicines is expected to drive growth with 20-30 annual launches and biosimilars. Specialty faces ...

President Donald Trump’s top health advisers announced a push to cut health costs by bringing more cutting-edge generic drugs to market in a press conference on Wednesday. The Food and Drug ...

Companies are investing heavily in complex injectables, respiratory therapies and biosimilars to improve margins and ...

India's pharmaceutical industry, backed by $30 billion exports, is transitioning from generics to specialty medicines, biologics, and AI-driven manufacturing.

Amneal Pharmaceuticals (NASDAQ:AMRX) Co-Founder, President and Co-Chief Executive Officer Chirag Patel said the company is entering a stronger growth phase, driven by momentum in its existing generics ...